Daré Bioscience Receives $3.6 Million in Additional Grant Funding

Core Insights - Daré Bioscience, Inc. has received approximately $3.6 million from the Gates Foundation to support the development of a non-hormonal intravaginal contraceptive aimed at women in low- and middle-income countries [1][2][3] Funding and Grant Details - The recent payment is part of a larger grant agreement totaling approximately $10.7 million, originally announced in November 2024, reflecting the company's achievement of key development milestones [2][4] - An initial payment of approximately $5.4 million was received in 2024, with future payments contingent on the achievement of additional milestones [4] Product Development Focus - The funding will support activities related to product design, formulation, acceptability, and early-stage development, which will inform subsequent clinical development [3][4] - The company is advancing its investigational hormone-free monthly intravaginal contraceptive, Ovaprene®, which is currently in a pivotal Phase 3 study [3] Company Mission and Vision - Daré Bioscience is dedicated to closing the gap in women's health by developing innovative solutions based on advanced science and rigorous research [5][6] - The company aims to provide non-hormonal, user-controlled contraceptive methods that align with women's preferences, particularly in LMIC settings [3][4]